Design Therapeutics Inc. Common Stock

Design Therapeutics Inc. a preclinical-stage biopharmaceutical company engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia a monogenic autosomal recessive progressive multi-system disease that affects organ systems dependent on mitochondrial function eventually leading to neurological cardiac and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1) a dominantly-inherited monogenic progressive neuromuscular disease affecting skeletal muscle heart brain and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases such as Fragile X syndrome spinocerebellar ataxias amyotrophic lateral sclerosis frontotemporal dementia Huntington disease and spinobulbar muscular atrophy. The company was incorporated in 2017 and is headquartered in Carlsbad California.